Research programme: targeted inflammation and autoimmune therapeutics - Affibody/Swedish Orphan Biovitrum

Drug Profile

Research programme: targeted inflammation and autoimmune therapeutics - Affibody/Swedish Orphan Biovitrum

Alternative Names: IL-1 Affibody; SOBI 005; SOBI 006; Z-FC

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Affibody; Biovitrum
  • Developer Affibody; Swedish Orphan Biovitrum
  • Class Proteins
  • Mechanism of Action Complement C5 inhibitors; Immunomodulators; Immunosuppressants; Interleukin 1 beta inhibitors; Interleukin 1 modulators; Th17 cell inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Autoimmune disorders
  • No development reported Inflammation

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammation in Sweden (Parenteral)
  • 22 Apr 2016 Swedish Orphan Biovitrum signs licensing agreement with Affibody for therapeutics targeting interleukin-1 for inflammatory diseases
  • 24 Nov 2015 Preclinical trials in Autoimmune disorders in Sweden (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top